Hypercalcemia

Definition

Hypercalcaemia (in American English, hypercalcemia) is an elevated calcium level in the blood. (Normal range: 9–10.5 mg/dL or 2.2–2.6 mmol/L). It can be an asymptomatic laboratory finding, but because an elevated calcium level is often indicative of other diseases, a workup should be undertaken if it persists. It can be due to excessive skeletal calcium release, increased intestinal calcium absorption, or decreased renal calcium excretion.

Signs and Symptoms 

There is a general mnemonic for remembering the effects of hypercalcaemia: "groans (constipation), moans (psychic moans (e.g., fatigue, lethargy, depression)), bones (bone pain, especially if PTH is elevated), stones (kidney stones), and psychiatric overtones (including depression and confusion)."

Other symptoms can include fatigue, anorexia, nausea, vomiting, pancreatitis and increased urination.

Abnormal heart rhythms can result, and ECG findings of a short QT interval and a widened T wave suggest hypercalcaemia. Significant hypercalcaemia can cause ECG changes mimicking an acute myocardial infarction.

Peptic ulcers may also occur.

Symptoms are more common at high blood calcium values (12.0 mg/dL or 3 mmol/L). Severe hypercalcaemia (above 15–16 mg/dL or 3.75–4 mmol/L) is considered a medical emergency: at these levels, coma and cardiac arrest can result.

Causes

Known causes can be grouped into 5 types: 1) Abnormal parathyroid gland function, 2) Malignancy, 3) Vitamin D metabolic disorders, 4) Disorders related to high bone-turnover rates, and 5) Renal failure.

Primary hyperparathyroidism and malignancy account for about 90% of cases of hypercalcaemia.

Abnormal parathyroid gland function

• primary hyperparathyroidism (see Parathyroid in New World Encyclopedia)
  
  • solitary parathyroid adenoma
  • primary parathyroid hyperplasia
  • parathyroid carcinoma
  • multiple endocrine neoplasia (MEN)
  • familial isolated hyperparathyroidism
• lithium use
• familial hypocalciuric hypercalcaemia/familial benign hypercalcaemia

Malignancy

• solid tumour with metastasis (e.g. breast cancer or classically squamous cell carcinoma, which can be PTHrP-mediated)
• solid tumour with humoral mediation of hypercalcaemia (e.g. lung cancer [most commonly non-small cell lung cancer] or kidney cancer, phaeochromocytoma)
• haematologic malignancy (multiple myeloma, lymphoma, leukaemia)

Vitamin D metabolic disorders

• hypervitaminosis D (vitamin D intoxication)
• elevated 1,25(OH)₂D (see calcitriol under Vitamin D) levels (e.g. sarcoidosis and other granulomatous diseases)
• idiopathic hypercalcaemia of infancy
• rebound hypercalcaemia after rhabdomyolysis

Disorders related to high bone-turnover rates

• hyperthyroidism
• prolonged immobilization
• thiazide use
• vitamin A intoxication
• Paget's disease of the bone
• multiple myeloma

Renal failure

• severe secondary hyperparathyroidism
• aluminium intoxication
• milk-alkali syndrome

Treatment

The goal of therapy is to treat the hypercalcaemia first and subsequently effort is directed to treat the underlying cause. Treating hypovolemia should come first and treatment is systematic, treat one thing at a time. Overtreating hypovolemia leads to edema.

There are 3 treatment modes: 1) Initial therapy (fluids and diuretics), 2) Additional therapy (bisphosphonates and calcitonin), and 3) Other therapies.

Initial therapy (fluids and diuretics)

Hydration, increasing salt intake, and forced diuresis.

• hydration is needed because many patients are dehydrated due to vomiting or renal defects in concentrating urine.
• increased salt intake also can increase body fluid volume as well as increasing urine sodium excretion, which further increases urinary calcium excretion (In other words, calcium and sodium (salt) are handled in a similar way by the kidney. Anything that causes increased sodium (salt) excretion by the kidney will, en passant, cause increased calcium excretion by the kidney)
• after rehydration, a loop diuretic such as furosemide can be given to permit continued large volume intravenous salt and water replacement while minimizing the risk of blood volume overload and pulmonary oedema. In addition, loop diuretics tend to depress renal calcium reabsorption thereby helping to lower blood calcium levels
• can usually decrease serum calcium by 1–3 mg/dL within 24 h
• caution must be taken to prevent potassium or magnesium depletion

Additional therapy (bisphosphonates and calcitonin)

• bisphosphonates are pyrophosphate analogues with high affinity for bone, especially areas of high bone-turnover.
  • they are taken up by osteoclasts and inhibit osteoclastic bone resorption
  • current available drugs include (in order of potency): (1st gen) etidronate, (2nd gen) tiludronate, IV pamidronate, alendronate (3rd gen) zoledronate and risedronate
  • all patients with cancer-associated hypercalcaemia should receive treatment with bisphosphonates since the 'first line' therapy (above) cannot be continued indefinitely nor is it without risk. Further, even if the 'first line' therapy has been effective, it is a virtual certainty that the hypercalcaemia will recur in the patient with hypercalcaemia of malignancy. Use of bisphosphonates in such circumstances, then, becomes both therapeutic and preventative
  • patients in renal failure and hypercalcaemia should have a risk-benefit analysis before being given bisphosphonates, since they are relatively contraindicated in renal failure.

• Calcitonin blocks bone resorption and also increases urinary calcium excretion by inhibiting renal calcium reabsorption
  • Usually used in life-threatening hypercalcaemia along with rehydration, diuresis, and bisphosphonates
  • Helps prevent recurrence of hypercalcaemia
  • Dose is 4 Units per kg via subcutaneous or intramuscular route every 12 hours, usually not continued indefinitely

Other therapies

Rarely used, or used in special circumstances

• plicamycin inhibits bone resorption (rarely used)
• gallium nitrate inhibits bone resorption and changes structure of bone crystals (rarely used)
• glucocorticoids increase urinary calcium excretion and decrease intestinal calcium absorption
  • no effect on calcium level in normal or primary hyperparathyroidism
  • effective in hypercalcaemia due to osteolytic malignancies (multiple myeloma, leukaemia, Hodgkin's lymphoma, carcinoma of the breast) due to antitumor properties
  • also effective in hypervitaminosis D and sarcoidosis
• dialysis usually used in severe hypercalcaemia complicated by renal failure. Supplemental phosphate should be monitored and added if necessary
• phosphate therapy can correct the hypophosphataemia in the face of hypercalcaemia and lower serum calcium

Emergency - Hypercalcaemic crisis

A hypercalcaemic crisis is an emergency situation with a severe hypercalcaemia, generally above approximately 14 mg/dL (or 3.5 mmol/L).

The main symptoms of a hypercalcaemic crisis are oliguria or anuria, as well as somnolence or coma.

After recognition, primary hyperparathyroidism should be proved or excluded.

In extreme cases of primary hyperparathyroidism, removal of the parathyroid gland after surgical neck exploration is the only way to avoid death. The diagnostic program should be performed within hours, in parallel with measures to lower serum calcium. Treatment of choice for acutely lowering calcium is extensive hydration and calcitonin, as well as bisphosphonates (which have effect on calcium levels after one or two days).


Source: Wikipedia